2024 Scientific Sessions

OR02-2
TRENDS AND OUTCOMES OF MECHANICAL CIRCULATORY SUPPORT AND HEART TRANSPLANT

Presenter

Marjolein Le, Memorial Healthcare System, Pembroke Pines, FL
Pyi Phyo Aung, MD1, Kyeeun Park, MD2, Marjolein Le1 and Htoo Myat Nge1, (1)Memorial Healthcare System, Pembroke Pines, FL, (2)Memorial Healthcare System, Miramar, FL

Keywords: Cardiogenic Shock, Heart Failure and Hemodynamic Support

Background


The use of mechanical circulatory support (MCS) devices in heart transplant cases has been growing over the years, serving as a bridge to transplantation for those awaiting for a suitable donor heart. Despite the increased utilization, comprehensive data on MCS outcome in heart transplant patients remains limited.

Methods


A retrospective analysis was conducted using data from the Nationwide Inpatient Sample spanning from 2016 to 2019. Adult patients (age >18 years) who underwent heart transplant were identified using ICD-10-CM diagnosis and procedure codes. Patients who received MCS were identified. National estimates were derived using discharge-level weight analysis. Univariate and multivariable hierarchical regression analyses were used to determine the odds ratios (ORs).

Results


Between 2016 and 2019, a total of 11,300 patients underwent heart transplant. Among them, 3,085 (27.3%) received MCS, with its utilization increasing annually from 525, 515, 645 and 1,400 cases in 2016, 2017, 2018 and 2019 (p<0.0001) respectively. Both groups-those with and without MCS had comparable proportions of females (28.0% vs 28.4%) and mean ages (54.1 years vs 53.4 years). However, patients with MCS were more likely to of African American (26.1% vs 21.1%) and less co-morbidities including diabetes mellitus (26.3% vs 33.5%) and chronic kidney disease (22.0% vs 25.4%).In MCS group, there were higher rates of in-hospital mortality (12.8% vs 2.9%), cardiogenic shock (75.&% vs 37.7%), ischemic stroke (4.9% vs 3.2%), hemorrhagic stroke (3.1% vs 1.0%) and lower requirement for blood transfusion (13.1% vs 19.2%). The cost of hospitalization is higher in MCS group ($1,322,352 vs $877,340.7) and the mean cost of each MCS patient was $1,476,950.

Conclusions


There has been a yearly rise in the usage of MCS in heart transplants, with a significant surge observed in 2019 following the 2018 UNOS heart allocation policy revision. This increased was accompanied by increased rates of in-hospital mortality and post-procedural complications.